Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381

1.

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.

Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, Beaven A, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM.

Clin Cancer Res. 2019 Sep 3. doi: 10.1158/1078-0432.CCR-19-0438. [Epub ahead of print]

PMID:
31481504
2.

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).

Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN Jr.

J Clin Oncol. 2019 Oct 10;37(29):2682-2688. doi: 10.1200/JCO.19.00861. Epub 2019 Aug 7.

PMID:
31390274
3.

Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.

Ji L, Lewinger JP, Krailo M, Groshen S, Conti DV, Asgharzadeh S, Sposto R.

Pharm Stat. 2019 Jun 25. doi: 10.1002/pst.1955. [Epub ahead of print]

PMID:
31237419
4.

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).

Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME.

Clin Genitourin Cancer. 2019 Aug;17(4):241-247.e1. doi: 10.1016/j.clgc.2019.02.010. Epub 2019 Mar 19.

PMID:
31227432
5.

Identifying Predictors of Outcomes in Combined Heart and Liver Transplantation.

Lee S, Matsuoka L, Cao S, Groshen S, Alexopoulos SP.

Transplant Proc. 2019 Jul - Aug;51(6):2002-2008. doi: 10.1016/j.transproceed.2019.04.038. Epub 2019 Jun 18.

PMID:
31227300
6.

Clinical outcomes of patients with pemphigus treated by the same physicians in a public safety net healthcare system vs. a private healthcare system.

Kasperkiewicz M, Lai O, Recke A, Betlachin A, Ji L, Groshen S, Woodley D.

Br J Dermatol. 2019 Oct;181(4):850-852. doi: 10.1111/bjd.17983. Epub 2019 Jul 21. No abstract available.

PMID:
30959576
7.
8.

The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study.

Kraus RD, Barsky A, Ji L, Garcia Santos PM, Cheng N, Groshen S, Vapiwala N, Ballas LK.

Adv Radiat Oncol. 2018 Sep 19;4(1):96-102. doi: 10.1016/j.adro.2018.09.006. eCollection 2019 Jan-Mar.

9.

Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.

Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):50-60. doi: 10.1016/j.ijrobp.2018.12.047. Epub 2018 Dec 31.

PMID:
30605751
10.

Contrast-Enhanced Ultrasound Imaging of Breast Masses: Adjunct Tool to Decrease the Number of False-Positive Biopsy Results.

Lee SC, Tchelepi H, Grant E, Desai B, Luo C, Groshen S, Hovanessian-Larsen L.

J Ultrasound Med. 2019 Sep;38(9):2259-2273. doi: 10.1002/jum.14917. Epub 2018 Dec 31.

PMID:
30597640
11.

Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.

Yap KK, Wong W, Ji L, Groshen S, Quinn DI, Bryce AH, Dorff TB.

Cancer Treat Res Commun. 2019;18:100114. doi: 10.1016/j.ctarc.2018.100114. Epub 2018 Nov 10.

PMID:
30529990
12.

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.

Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM.

BMC Cancer. 2018 Oct 11;18(1):970. doi: 10.1186/s12885-018-4880-x.

13.

Biliary-Enteric Drainage vs Primary Liver Transplant as Initial Treatment for Children With Biliary Atresia.

LeeVan E, Matsuoka L, Cao S, Groshen S, Alexopoulos S.

JAMA Surg. 2019 Jan 1;154(1):26-32. doi: 10.1001/jamasurg.2018.3180.

14.

Predictive Value of FDG PET/CT to Detect Lymph Node Metastases in Cervical Cancer.

Brunette LL, Bonyadlou S, Ji L, Groshen S, Shuster D, Mehta A, Sposto R, Matsuo K, Lin YG, Roman LD.

Clin Nucl Med. 2018 Nov;43(11):793-801. doi: 10.1097/RLU.0000000000002252.

PMID:
30153151
15.

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.

Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM.

Cancer Chemother Pharmacol. 2018 Oct;82(4):723-732. doi: 10.1007/s00280-018-3672-y. Epub 2018 Aug 20.

16.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A.

Clin Cancer Res. 2018 Dec 15;24(24):6142-6149. doi: 10.1158/1078-0432.CCR-18-1381. Epub 2018 Aug 9.

PMID:
30093449
17.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D.

Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6.

PMID:
30082475
18.

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR.

Pediatr Blood Cancer. 2018 Jul;65(7):e27023. doi: 10.1002/pbc.27023. Epub 2018 Mar 30.

19.

Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?

Ballas LK, Kraus R, Ji L, Groshen S, Stern MC, Gill I, Quinn DI, Chung E, Abreu A, Hamilton AS.

Clin Genitourin Cancer. 2018 Aug;16(4):e719-e727. doi: 10.1016/j.clgc.2018.01.018. Epub 2018 Feb 6.

PMID:
29483045
20.

Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients.

Loh JM, Tran AL, Ji L, Groshen S, Daneshmand S, Schuckman A, Quinn DI, Dorff TB.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30271-9. doi: 10.1016/j.clgc.2017.08.016. [Epub ahead of print]

PMID:
28958673
21.

Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL.

Oncotarget. 2016 Nov 18;8(32):52193-52210. doi: 10.18632/oncotarget.13386. eCollection 2017 Aug 8.

22.

Attitudes and barriers to the use of donation after cardiac death livers: Comparison of a United States transplant center survey to the united network for organ sharing data.

Sher L, Quintini C, Fayek SA, Abt P, Lo M, Yuk P, Ji L, Groshen S, Case J, Marsh CL.

Liver Transpl. 2017 Nov;23(11):1372-1383. doi: 10.1002/lt.24855.

23.

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.

Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J.

Clin Genitourin Cancer. 2017 Dec;15(6):742-749. doi: 10.1016/j.clgc.2017.06.002. Epub 2017 Jun 8.

PMID:
28668277
24.

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.

Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC.

Clin Cancer Res. 2017 Sep 15;23(18):5374-5383. doi: 10.1158/1078-0432.CCR-16-2647. Epub 2017 May 30.

25.

Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease.

Nadim MK, DiNorcia J, Ji L, Groshen S, Levitsky J, Sung RS, Kim WR, Andreoni K, Mulligan D, Genyk YS.

J Hepatol. 2017 Sep;67(3):517-525. doi: 10.1016/j.jhep.2017.04.022. Epub 2017 May 5.

PMID:
28483678
26.

GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice.

Shen J, Ha DP, Zhu G, Rangel DF, Kobielak A, Gill PS, Groshen S, Dubeau L, Lee AS.

Proc Natl Acad Sci U S A. 2017 May 16;114(20):E4020-E4029. doi: 10.1073/pnas.1616060114. Epub 2017 May 1.

27.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.

Mohrbacher AM, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman EM, Maurer BJ.

Clin Cancer Res. 2017 Aug 15;23(16):4550-4555. doi: 10.1158/1078-0432.CCR-17-0234. Epub 2017 Apr 18.

28.

No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses.

Bian SX, Korah MP, Whitaker TR, Ji L, Groshen S, Chung E.

Clin Breast Cancer. 2017 Nov;17(7):510-515. doi: 10.1016/j.clbc.2017.03.011. Epub 2017 Mar 23.

PMID:
28412326
29.

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ.

Eur J Cancer. 2017 May;77:13-20. doi: 10.1016/j.ejca.2017.02.020. Epub 2017 Mar 26.

PMID:
28347919
30.

Improvement in the Outcomes of MELD ≥ 40 Liver Transplantation: An Analysis of 207 Consecutive Transplants in a Highly Competitive DSA.

Nekrasov V, Matsuoka L, Kaur N, Pita A, Whang G, Cao S, Groshen S, Alexopoulos S.

Transplantation. 2017 Oct;101(10):2360-2367. doi: 10.1097/TP.0000000000001738.

PMID:
28319564
31.

Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease.

Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD.

Sci Transl Med. 2017 Feb 15;9(377). pii: eaai8700. doi: 10.1126/scitranslmed.aai8700.

32.

Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.

Lee SC, Grant E, Sheth P, Garcia AA, Desai B, Ji L, Groshen S, Hwang D, Yamashita M, Hovanessian-Larsen L.

J Ultrasound Med. 2017 May;36(5):901-911. doi: 10.7863/ultra.16.05060. Epub 2017 Feb 2.

PMID:
28150325
33.

Effects of Prolonged GRP78 Haploinsufficiency on Organ Homeostasis, Behavior, Cancer and Chemotoxic Resistance in Aged Mice.

Lee AS, Brandhorst S, Rangel DF, Navarrete G, Cohen P, Longo VD, Chen J, Groshen S, Morgan TE, Dubeau L.

Sci Rep. 2017 Feb 1;7:40919. doi: 10.1038/srep40919.

34.

Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery.

Bian SX, Routman D, Liu J, Yang D, Groshen S, Zada G, Trakul N, Wong MK, Yu C, Chang EL.

J Neurosurg. 2016 Dec;125(Suppl 1):31-39.

PMID:
27903181
35.

Effects of recipient size and allograft type on pediatric liver transplantation for biliary atresia.

Alexopoulos SP, Nekrasov V, Cao S, Groshen S, Kaur N, Genyk YS, Matsuoka L.

Liver Transpl. 2017 Feb;23(2):221-233. doi: 10.1002/lt.24675.

36.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

37.

Safety and feasibility of fasting in combination with platinum-based chemotherapy.

Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI.

BMC Cancer. 2016 Jun 10;16:360. doi: 10.1186/s12885-016-2370-6.

38.

OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin.

Piatek CI, Tagawa ST, Wei-Tsai D, Hanna D, Weitz IC, O'Connell C, Rochanda L, Groshen S, Liebman HA.

Thromb Res. 2016 Apr;140 Suppl 1:S174. doi: 10.1016/S0049-3848(16)30131-1. Epub 2016 Apr 8.

PMID:
27161687
39.

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP.

Pediatr Blood Cancer. 2016 Aug;63(8):1349-56. doi: 10.1002/pbc.25994. Epub 2016 Apr 19.

PMID:
27092812
40.

Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice.

Press MF, Villalobos I, Santiago A, Guzman R, Cervantes M, Gasparyan A, Campeau A, Ma Y, Tsao-Wei DD, Groshen S.

Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print]

PMID:
27081877
41.

National Outcomes of Liver Transplantation for Model for End-Stage Liver Disease Score ≥40: The Impact of Share 35.

Nekrasov V, Matsuoka L, Rauf M, Kaur N, Cao S, Groshen S, Alexopoulos SP.

Am J Transplant. 2016 Oct;16(10):2912-2924. doi: 10.1111/ajt.13823. Epub 2016 May 13.

42.

RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.

Chimge NO, Little GH, Baniwal SK, Adisetiyo H, Xie Y, Zhang T, O'Laughlin A, Liu ZY, Ulrich P, Martin A, Mhawech-Fauceglia P, Ellis MJ, Tripathy D, Groshen S, Liang C, Li Z, Schones DE, Frenkel B.

Nat Commun. 2016 Feb 26;7:10751. doi: 10.1038/ncomms10751.

43.

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP.

J Clin Oncol. 2016 Apr 20;34(12):1368-75. doi: 10.1200/JCO.2015.65.4889. Epub 2016 Feb 16.

44.

Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.

Kushal S, Wang W, Vaikari VP, Kota R, Chen K, Yeh TS, Jhaveri N, Groshen SL, Olenyuk BZ, Chen TC, Hofman FM, Shih JC.

Oncotarget. 2016 Mar 22;7(12):13842-53. doi: 10.18632/oncotarget.7283.

45.

Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.

Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS.

Oncologist. 2016 Feb;21(2):172-7. doi: 10.1634/theoncologist.2015-0319. Epub 2016 Jan 19.

46.

AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.

Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A.

Prostate. 2016 May;76(6):597-608. doi: 10.1002/pros.23151. Epub 2016 Jan 15.

PMID:
26771938
47.

Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.

Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL.

Thyroid. 2016 Mar;26(3):381-9. doi: 10.1089/thy.2015.0289. Epub 2016 Feb 10.

48.

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ.

Clin Cancer Res. 2015 Nov 15;21(22):5057-63. doi: 10.1158/1078-0432.CCR-15-0035.

49.

Kidney transplantation in the Hispanic population.

Matsuoka L, Alicuben E, Woo K, Cao S, Groshen S, Qazi Y, Smogorzewski M, Selby R, Alexopoulos S.

Clin Transplant. 2016 Feb;30(2):118-23. doi: 10.1111/ctr.12662. Epub 2015 Dec 16.

PMID:
26529140
50.

Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables.

Sher LS, Levi DM, Wecsler JS, Lo M, Petrovic LM, Groshen S, Ji L, Uso TD, Tector AJ, Hamilton AS, Marsh JW, Schwartz ME.

J Surg Oncol. 2015 Aug;112(2):125-32. doi: 10.1002/jso.23973. Epub 2015 Jul 14.

PMID:
26171686

Supplemental Content

Loading ...
Support Center